



Experiment Number: 20614 - 01

Test Type: CHRONIC

Route: DOSED FEED

Species/Strain: RATS/HSD

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Perfluorooctanoic Acid

CAS Number: 335-67-1

Date Report Requested: 07/25/2018

Time Report Requested: 12:58:26

First Dose M/F: 10/27/08 / 10/28/08

Lab: BAT

| Harlan Sprague Dawley RATS FEMALE | 0/0 ppm | 0/300 ppm | 150/300 ppm | 0/1000 ppm | 300/1000 ppm |
|-----------------------------------|---------|-----------|-------------|------------|--------------|
|-----------------------------------|---------|-----------|-------------|------------|--------------|

**Disposition Summary**

|   |           |           |           |           |           |
|---|-----------|-----------|-----------|-----------|-----------|
| <b>Animals Initially In Study</b>       | <b>60</b> | <b>60</b> | <b>60</b> | <b>60</b> | <b>60</b> |
| <b>Early Deaths</b>                     |           |           |           |           |           |
| <b>Moribund Sacrifice</b>               | <b>15</b> | <b>16</b> | <b>11</b> | <b>20</b> | <b>17</b> |
| <b>Natural Death</b>                    | <b>12</b> | <b>6</b>  | <b>7</b>  | <b>7</b>  | <b>10</b> |
| <b>Survivors</b>                        |           |           |           |           |           |
| <b>Natural Death</b>                    |           | <b>2</b>  |           |           | <b>1</b>  |
| <b>Terminal Sacrifice</b>               | <b>23</b> | <b>26</b> | <b>32</b> | <b>23</b> | <b>22</b> |
| <b>Animals Examined Microscopically</b> | <b>50</b> | <b>50</b> | <b>50</b> | <b>50</b> | <b>50</b> |

## ALIMENTARY SYSTEM

|                                   |          |          |          |         |         |
|-----------------------------------|----------|----------|----------|---------|---------|
| Esophagus                         | (50)     | (50)     | (50)     | (48)    | (50)    |
| Intestine Large, Cecum            | (50)     | (49)     | (50)     | (49)    | (50)    |
| Intestine Large, Colon            | (50)     | (49)     | (50)     | (49)    | (50)    |
| Parasite Metazoan                 | 1 (2%)   | 7 (14%)  | 8 (16%)  | 2 (4%)  | 7 (14%) |
| Intestine Large, Rectum           | (50)     | (49)     | (50)     | (49)    | (50)    |
| Inflammation, Focal               |          | 1 (2%)   |          |         |         |
| Intestine Small, Duodenum         | (50)     | (50)     | (50)     | (49)    | (50)    |
| Intestine Small, Ileum            | (50)     | (49)     | (50)     | (49)    | (50)    |
| Intestine Small, Jejunum          | (50)     | (49)     | (50)     | (49)    | (50)    |
| Liver                             | (50)     | (50)     | (50)     | (49)    | (50)    |
| Angiectasis                       | 2 (4%)   | 1 (2%)   |          | 1 (2%)  |         |
| Basophilic Focus                  | 11 (22%) | 8 (16%)  | 12 (24%) | 6 (12%) | 6 (12%) |
| Cholangiofibrosis                 |          |          |          |         | 1 (2%)  |
| Clear Cell Focus                  | 11 (22%) | 9 (18%)  | 8 (16%)  | 8 (16%) | 5 (10%) |
| Degeneration, Cystic              | 1 (2%)   |          | 1 (2%)   | 1 (2%)  | 1 (2%)  |
| Eosinophilic Focus                | 8 (16%)  | 1 (2%)   | 12 (24%) | 6 (12%) | 2 (4%)  |
| Extramedullary Hematopoiesis      | 13 (26%) | 7 (14%)  | 10 (20%) | 2 (4%)  | 1 (2%)  |
| Fatty Change, Focal               |          | 1 (2%)   |          |         |         |
| Hepatodiaphragmatic Nodule        | 2 (4%)   | 1 (2%)   |          |         | 1 (2%)  |
| Infiltration Cellular, Mixed Cell | 1 (2%)   |          |          |         |         |
| Inflammation, Focal               | 6 (12%)  | 10 (20%) | 6 (12%)  | 7 (14%) | 6 (12%) |
| Mixed Cell Focus                  | 1 (2%)   |          | 1 (2%)   |         |         |
| Necrosis                          |          | 1 (2%)   | 4 (8%)   | 8 (16%) | 5 (10%) |

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20614 - 01

Test Type: CHRONIC

Route: DOSED FEED

Species/Strain: RATS/HSD

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Perfluorooctanoic Acid

CAS Number: 335-67-1

Date Report Requested: 07/25/2018

Time Report Requested: 12:58:26

First Dose M/F: 10/27/08 / 10/28/08

Lab: BAT

| Harlan Sprague Dawley RATS FEMALE                    | 0/0 ppm  | 0/300 ppm | 150/300 ppm | 0/1000 ppm | 300/1000 ppm |
|--|----------|-----------|-------------|------------|--------------|
| Pigment  | 3 (6%)   | 5 (10%)   | 10 (20%)    | 43 (88%)   | 40 (80%)     |
| Bile Duct, Cyst                                      | 9 (18%)  | 6 (12%)   | 5 (10%)     | 2 (4%)     | 5 (10%)      |
| Bile Duct, Hyperplasia                               | 16 (32%) | 25 (50%)  | 27 (54%)    | 22 (45%)   | 27 (54%)     |
| Centrilobular, Fatty Change, Microvesicular, Diffuse |          |           |             | 1 (2%)     |              |
| Centrilobular, Necrosis                              |          | 4 (8%)    | 2 (4%)      | 3 (6%)     | 3 (6%)       |
| Hepatocyte, Cytoplasmic Alteration                   |          | 9 (18%)   | 17 (34%)    | 49 (100%)  | 49 (98%)     |
| Hepatocyte, Hyperplasia                              |          |           |             | 1 (2%)     |              |
| Hepatocyte, Hypertrophy                              |          | 11 (22%)  | 16 (32%)    | 48 (98%)   | 49 (98%)     |
| Hepatocyte, Increased Mitoses                        | 2 (4%)   | 3 (6%)    | 5 (10%)     | 4 (8%)     | 10 (20%)     |
| Hepatocyte, Single Cell Death                        |          | 4 (8%)    | 5 (10%)     | 29 (59%)   | 32 (64%)     |
| Kupffer Cell, Hyperplasia                            |          |           |             | 1 (2%)     |              |
| Oval Cell, Hyperplasia                               | 1 (2%)   |           |             | 2 (4%)     | 3 (6%)       |
| Mesentery  | (2)      | (0)       | (0)         | (2)        | (0)          |
| Hemorrhage   |          |           |             | 2 (100%)   |              |
| Oral Mucosa  | (0)      | (0)       | (0)         | (0)        | (1)          |
| Pancreas   | (50)     | (50)      | (50)        | (49)       | (50)         |
| Basophilic Focus                                     |          |           | 1 (2%)      |            |              |
| Inflammation, Chronic Active                         |          |           | 1 (2%)      |            |              |
| Necrosis   |          |           |             | 1 (2%)     |              |
| Acinus, Atrophy                                      |          | 3 (6%)    | 4 (8%)      | 2 (4%)     | 1 (2%)       |
| Acinus, Hyperplasia                                  |          | 1 (2%)    |             | 1 (2%)     | 1 (2%)       |
| Duct, Inflammation, Granulomatous                    |          |           |             | 1 (2%)     |              |
| Salivary Glands                                      | (49)     | (50)      | (50)        | (48)       | (50)         |
| Stomach, Forestomach                                 | (50)     | (50)      | (50)        | (49)       | (50)         |
| Inflammation, Chronic Active                         |          |           | 1 (2%)      |            |              |
| Mineral  |          |           |             | 1 (2%)     |              |
| Ulcer  | 2 (4%)   | 2 (4%)    | 1 (2%)      | 9 (18%)    | 11 (22%)     |
| Epithelium, Hyperplasia                              | 4 (8%)   | 5 (10%)   | 3 (6%)      | 22 (45%)   | 21 (42%)     |
| Muscularis, Degeneration                             |          |           |             |            | 1 (2%)       |
| Submucosa, Inflammation, Chronic Active              | 3 (6%)   | 2 (4%)    | 2 (4%)      | 16 (33%)   | 18 (36%)     |
| Stomach, Glandular                                   | (50)     | (50)      | (50)        | (49)       | (50)         |
| Inflammation   |          |           |             |            | 1 (2%)       |
| Epithelium, Necrosis                                 |          |           |             | 1 (2%)     |              |
| Mucosa, Mineral                                      |          | 1 (2%)    |             | 2 (4%)     | 2 (4%)       |
| Submucosa, Inflammation, Chronic Active              |          |           |             |            | 2 (4%)       |

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20614 - 01

Test Type: CHRONIC

Route: DOSED FEED

Species/Strain: RATS/HSD

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Perfluorooctanoic Acid

CAS Number: 335-67-1

Date Report Requested: 07/25/2018

Time Report Requested: 12:58:26

First Dose M/F: 10/27/08 / 10/28/08

Lab: BAT

| Harlan Sprague Dawley RATS FEMALE | 0/0 ppm  | 0/300 ppm | 150/300 ppm | 0/1000 ppm | 300/1000 ppm |
|-----------------------------------|----------|-----------|-------------|------------|--------------|
| Submucosa, Mineral                |          |           |             |            | 1 (2%)       |
| <b>CARDIOVASCULAR SYSTEM</b>      |          |           |             |            |              |
| Blood Vessel                      | (50)     | (50)      | (50)        | (49)       | (50)         |
| Inflammation                      |          | 1 (2%)    | 2 (4%)      | 1 (2%)     |              |
| Aorta, Mineral                    | 1 (2%)   | 1 (2%)    | 2 (4%)      |            | 1 (2%)       |
| Heart                             | (50)     | (50)      | (50)        | (48)       | (50)         |
| Cardiomyopathy                    | 8 (16%)  | 5 (10%)   | 13 (26%)    | 4 (8%)     | 4 (8%)       |
| Mineral                           |          | 1 (2%)    | 1 (2%)      |            | 1 (2%)       |
| Necrosis, Acute                   |          |           | 1 (2%)      |            |              |
| Schwann Cell, Hyperplasia         | 1 (2%)   |           |             |            |              |
| <b>ENDOCRINE SYSTEM</b>           |          |           |             |            |              |
| Adrenal Cortex                    | (50)     | (50)      | (50)        | (49)       | (50)         |
| Atrophy                           |          |           | 1 (2%)      |            |              |
| Degeneration, Cystic              | 11 (22%) | 8 (16%)   | 11 (22%)    | 9 (18%)    | 7 (14%)      |
| Hypertrophy                       | 2 (4%)   | 2 (4%)    | 5 (10%)     |            | 3 (6%)       |
| Hypertrophy, Focal                |          |           |             |            | 1 (2%)       |
| Necrosis                          |          | 1 (2%)    |             |            | 1 (2%)       |
| Vacuolization Cytoplasmic         | 1 (2%)   | 1 (2%)    |             | 5 (10%)    | 4 (8%)       |
| Zona Fasciculata, Hyperplasia     |          |           | 2 (4%)      |            |              |
| Adrenal Medulla                   | (50)     | (50)      | (50)        | (49)       | (50)         |
| Hyperplasia                       | 7 (14%)  | 14 (28%)  | 8 (16%)     | 12 (24%)   | 8 (16%)      |
| Islets, Pancreatic                | (50)     | (50)      | (50)        | (49)       | (50)         |
| Hyperplasia                       | 3 (6%)   |           |             | 1 (2%)     | 1 (2%)       |
| Parathyroid Gland                 | (47)     | (47)      | (42)        | (46)       | (48)         |
| Cytoplasmic Alteration            |          |           |             |            | 1 (2%)       |
| Hyperplasia, Focal                | 1 (2%)   |           |             |            |              |
| Pituitary Gland                   | (50)     | (50)      | (50)        | (49)       | (50)         |
| Angiectasis                       |          | 1 (2%)    |             |            |              |
| Cyst                              |          | 1 (2%)    |             |            |              |
| Necrosis                          |          |           |             |            | 1 (2%)       |
| Pars Distalis, Hyperplasia        | 14 (28%) | 18 (36%)  | 26 (52%)    | 13 (27%)   | 7 (14%)      |

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20614 - 01

Test Type: CHRONIC

Route: DOSED FEED

Species/Strain: RATS/HSD

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Perfluorooctanoic Acid

CAS Number: 335-67-1

Date Report Requested: 07/25/2018

Time Report Requested: 12:58:26

First Dose M/F: 10/27/08 / 10/28/08

Lab: BAT

| Harlan Sprague Dawley RATS FEMALE | 0/0 ppm  | 0/300 ppm | 150/300 ppm | 0/1000 ppm | 300/1000 ppm |
|-----------------------------------|----------|-----------|-------------|------------|--------------|
| Rathke's Cleft, Hyperplasia       |          |           | 1 (2%)      |            |              |
| Thyroid Gland                     | (50)     | (50)      | (50)        | (48)       | (50)         |
| C-cell, Hyperplasia               | 10 (20%) | 4 (8%)    | 6 (12%)     | 7 (15%)    | 11 (22%)     |
| Follicular Cell, Hypertrophy      | 4 (8%)   | 8 (16%)   | 9 (18%)     | 28 (58%)   | 19 (38%)     |

GENERAL BODY SYSTEM

None

GENITAL SYSTEM

|                                   |          |          |          |          |          |
|-----------------------------------|----------|----------|----------|----------|----------|
| Clitoral Gland                    | (50)     | (49)     | (50)     | (48)     | (50)     |
| Hyperplasia, Squamous             | 1 (2%)   | 1 (2%)   |          | 1 (2%)   |          |
| Inflammation                      | 1 (2%)   |          |          |          | 1 (2%)   |
| Duct, Cyst                        |          |          | 1 (2%)   |          |          |
| Duct, Metaplasia, Squamous        | 1 (2%)   |          |          |          |          |
| Ovary                             | (50)     | (49)     | (50)     | (49)     | (50)     |
| Atrophy                           | 35 (70%) | 32 (65%) | 40 (80%) | 28 (57%) | 31 (62%) |
| Cyst                              | 16 (32%) | 20 (41%) | 16 (32%) | 16 (33%) | 23 (46%) |
| Inflammation                      |          | 1 (2%)   |          |          |          |
| Oviduct                           | (0)      | (1)      | (0)      | (0)      | (0)      |
| Uterus                            | (50)     | (49)     | (50)     | (49)     | (50)     |
| Adenomyosis                       | 1 (2%)   |          |          |          |          |
| Dilation                          | 2 (4%)   | 3 (6%)   |          | 3 (6%)   | 3 (6%)   |
| Hemorrhage                        |          |          |          | 1 (2%)   |          |
| Inflammation                      |          | 1 (2%)   |          |          |          |
| Inflammation, Suppurative         |          |          | 3 (6%)   | 4 (8%)   | 1 (2%)   |
| Inflammation, Acute               |          |          |          | 1 (2%)   | 1 (2%)   |
| Inflammation, Chronic Active      | 2 (4%)   |          |          |          |          |
| Thrombus                          |          | 1 (2%)   |          |          |          |
| Cervix, Hypertrophy               |          | 1 (2%)   | 1 (2%)   |          |          |
| Cervix, Inflammation, Suppurative |          |          |          | 1 (2%)   |          |
| Cervix, Stromal Hyperplasia       |          |          | 1 (2%)   |          |          |
| Endometrium, Hyperplasia          |          | 1 (2%)   |          |          |          |
| Endometrium, Hyperplasia, Cystic  | 20 (40%) | 22 (45%) | 31 (62%) | 18 (37%) | 18 (36%) |

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20614 - 01

Test Type: CHRONIC

Route: DOSED FEED

Species/Strain: RATS/HSD

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Perfluorooctanoic Acid

CAS Number: 335-67-1

Date Report Requested: 07/25/2018

Time Report Requested: 12:58:26

First Dose M/F: 10/27/08 / 10/28/08

Lab: BAT

| Harlan Sprague Dawley RATS FEMALE | 0/0 ppm  | 0/300 ppm | 150/300 ppm | 0/1000 ppm | 300/1000 ppm |
|-----------------------------------|----------|-----------|-------------|------------|--------------|
| Endometrium, Metaplasia, Squamous | 18 (36%) | 17 (35%)  | 21 (42%)    | 10 (20%)   | 11 (22%)     |
| Lymphatic, Angiectasis            |          |           | 1 (2%)      |            |              |
| Vagina                            | (0)      | (0)       | (0)         | (1)        | (0)          |

## HEMATOPOIETIC SYSTEM

|                                    |          |          |          |          |          |
|------------------------------------|----------|----------|----------|----------|----------|
| Bone Marrow                        | (50)     | (50)     | (50)     | (50)     | (50)     |
| Atrophy                            | 1 (2%)   |          |          | 4 (8%)   | 1 (2%)   |
| Hyperplasia                        | 21 (42%) | 20 (40%) | 22 (44%) | 29 (58%) | 28 (56%) |
| Lymph Node                         | (1)      | (3)      | (0)      | (3)      | (1)      |
| Mediastinal, Ectasia               |          |          |          | 1 (33%)  |          |
| Mediastinal, Hyperplasia, Lymphoid |          |          |          | 1 (33%)  |          |
| Lymph Node, Mandibular             | (48)     | (49)     | (49)     | (45)     | (48)     |
| Atrophy                            |          |          | 1 (2%)   | 1 (2%)   |          |
| Atrophy, Lymphoid                  | 4 (8%)   | 2 (4%)   | 1 (2%)   | 8 (18%)  | 10 (21%) |
| Hyperplasia, Lymphoid              | 1 (2%)   |          | 1 (2%)   | 1 (2%)   |          |
| Infiltration Cellular, Plasma Cell |          | 1 (2%)   | 2 (4%)   | 1 (2%)   |          |
| Lymph Node, Mesenteric             | (49)     | (48)     | (50)     | (48)     | (48)     |
| Atrophy, Lymphoid                  | 4 (8%)   | 3 (6%)   | 2 (4%)   | 8 (17%)  | 10 (21%) |
| Hyperplasia, Lymphoid              |          |          | 1 (2%)   |          |          |
| Spleen                             | (50)     | (50)     | (50)     | (49)     | (50)     |
| Extramedullary Hematopoiesis       | 34 (68%) | 33 (66%) | 36 (72%) | 29 (59%) | 28 (56%) |
| Infarct                            |          |          |          | 1 (2%)   |          |
| Pigment                            | 30 (60%) | 21 (42%) | 30 (60%) | 25 (51%) | 31 (62%) |
| Lymphoid Follicle, Atrophy         | 7 (14%)  | 9 (18%)  | 8 (16%)  | 13 (27%) | 20 (40%) |
| Lymphoid Follicle, Hyperplasia     |          | 2 (4%)   | 2 (4%)   | 1 (2%)   |          |
| Thymus                             | (49)     | (48)     | (50)     | (47)     | (47)     |
| Atrophy                            | 42 (86%) | 46 (96%) | 45 (90%) | 46 (98%) | 46 (98%) |

## INTEGUMENTARY SYSTEM

|               |          |          |          |          |          |
|---------------|----------|----------|----------|----------|----------|
| Mammary Gland | (50)     | (50)     | (50)     | (48)     | (50)     |
| Galactocele   |          |          | 2 (4%)   |          |          |
| Hyperplasia   | 13 (26%) | 15 (30%) | 13 (26%) | 19 (40%) | 15 (30%) |
| Inflammation  |          | 1 (2%)   |          |          |          |

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20614 - 01

Test Type: CHRONIC

Route: DOSED FEED

Species/Strain: RATS/HSD

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Perfluorooctanoic Acid

CAS Number: 335-67-1

Date Report Requested: 07/25/2018

Time Report Requested: 12:58:26

First Dose M/F: 10/27/08 / 10/28/08

Lab: BAT

| Harlan Sprague Dawley RATS FEMALE           | 0/0 ppm  | 0/300 ppm | 150/300 ppm | 0/1000 ppm | 300/1000 ppm |
|---|----------|-----------|-------------|------------|--------------|
| Skin  | (50)     | (50)      | (50)        | (49)       | (50)         |
| Cyst Epithelial Inclusion                   |          |           | 1 (2%)      |            |              |
| Ulcer                                       | 1 (2%)   |           |             |            |              |
| Epidermis, Sebaceous Gland, Hyperplasia     | 1 (2%)   |           |             |            |              |
| Subcutaneous Tissue, Inflammation           |          |           | 1 (2%)      |            |              |
| <b>MUSCULOSKELETAL SYSTEM</b>               |          |           |             |            |              |
| Bone  | (50)     | (50)      | (50)        | (50)       | (50)         |
| Skeletal Muscle                             | (0)      | (1)       | (1)         | (2)        | (0)          |
| <b>NERVOUS SYSTEM</b>                       |          |           |             |            |              |
| Brain                                       | (50)     | (50)      | (50)        | (49)       | (50)         |
| Gliosis, Diffuse                            | 1 (2%)   |           |             |            |              |
| Hemorrhage                                  | 2 (4%)   |           |             | 1 (2%)     |              |
| Necrosis                                    | 2 (4%)   |           | 1 (2%)      |            |              |
| Peripheral Nerve                            | (0)      | (0)       | (0)         | (1)        | (0)          |
| Degeneration                                |          |           |             | 1 (100%)   |              |
| Spinal Cord                                 | (1)      | (0)       | (0)         | (0)        | (0)          |
| <b>RESPIRATORY SYSTEM</b>                   |          |           |             |            |              |
| Lung  | (50)     | (50)      | (50)        | (48)       | (50)         |
| Cyst  |          |           |             | 1 (2%)     |              |
| Foreign Body                                |          |           |             | 1 (2%)     |              |
| Inflammation, Granulomatous, Multifocal     | 1 (2%)   | 1 (2%)    | 1 (2%)      | 3 (6%)     | 5 (10%)      |
| Inflammation, Chronic Active                | 2 (4%)   | 2 (4%)    | 7 (14%)     | 7 (15%)    | 7 (14%)      |
| Alveolus, Infiltration Cellular, Histiocyte | 36 (72%) | 33 (66%)  | 31 (62%)    | 40 (83%)   | 42 (84%)     |
| Nose  | (50)     | (50)      | (50)        | (50)       | (50)         |
| Foreign Body                                |          |           |             |            | 1 (2%)       |
| Inflammation                                | 3 (6%)   | 1 (2%)    | 1 (2%)      |            | 3 (6%)       |
| Olfactory Epithelium, Metaplasia            | 1 (2%)   |           |             |            |              |
| Respiratory Epithelium, Hyperplasia         | 1 (2%)   |           |             |            |              |

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20614 - 01

Test Type: CHRONIC

Route: DOSED FEED

Species/Strain: RATS/HSD

## P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Perfluorooctanoic Acid

CAS Number: 335-67-1

Date Report Requested: 07/25/2018

Time Report Requested: 12:58:26

First Dose M/F: 10/27/08 / 10/28/08

Lab: BAT

| Harlan Sprague Dawley RATS FEMALE                    | 0/0 ppm        | 0/300 ppm | 150/300 ppm | 0/1000 ppm | 300/1000 ppm |
|--|----------------|-----------|-------------|------------|--------------|
| Respiratory Epithelium, Metaplasia, Squamous Trachea | 1 (2%)<br>(50) | (50)      | (50)        | (48)       | (50)         |
| <b>SPECIAL SENSES SYSTEM</b>                         |                |           |             |            |              |
| Eye  | (50)           | (50)      | (50)        | (50)       | (50)         |
| Choroid, Inflammation                                |                |           | 1 (2%)      |            |              |
| Retina, Degeneration                                 | 1 (2%)         | 5 (10%)   |             | 1 (2%)     | 2 (4%)       |
| Harderian Gland                                      | (50)           | (50)      | (50)        | (49)       | (50)         |
| Hyperplasia  | 1 (2%)         |           |             |            |              |
| Zymbal's Gland                                       | (0)            | (0)       | (0)         | (0)        | (1)          |
| <b>URINARY SYSTEM</b>                                |                |           |             |            |              |
| Kidney   | (50)           | (50)      | (50)        | (49)       | (50)         |
| Accumulation, Hyaline Droplet                        | 3 (6%)         | 1 (2%)    |             | 1 (2%)     |              |
| Calculus Micro Observation Only                      | 11 (22%)       | 14 (28%)  | 12 (24%)    | 19 (39%)   | 16 (32%)     |
| Hemorrhage   |                |           |             | 1 (2%)     |              |
| Infarct  |                | 2 (4%)    |             | 5 (10%)    | 6 (12%)      |
| Inflammation, Chronic Active                         |                |           |             | 1 (2%)     |              |
| Nephropathy, Chronic Progressive                     | 37 (74%)       | 38 (76%)  | 35 (70%)    | 37 (76%)   | 46 (92%)     |
| Thrombus   |                |           |             | 1 (2%)     | 1 (2%)       |
| Cortex, Cyst   |                | 2 (4%)    | 2 (4%)      |            |              |
| Epithelium, Renal Tubule, Cytoplasmic Alteration     |                | 1 (2%)    |             |            |              |
| Papilla, Necrosis                                    |                |           |             | 12 (24%)   | 22 (44%)     |
| Papilla, Urothelium, Hyperplasia                     | 4 (8%)         | 21 (42%)  | 8 (16%)     | 40 (82%)   | 45 (90%)     |
| Pelvis, Dilatation                                   |                |           |             | 2 (4%)     | 1 (2%)       |
| Pelvis, Hemorrhage                                   |                |           |             |            | 1 (2%)       |
| Pelvis, Inflammation, Suppurative                    |                |           |             |            | 1 (2%)       |
| Pelvis, Inflammation, Chronic                        | 1 (2%)         |           |             | 4 (8%)     | 2 (4%)       |
| Renal Tubule, Dilatation                             |                | 1 (2%)    |             |            | 1 (2%)       |
| Renal Tubule, Hyperplasia, Atypical                  |                |           | 1 (2%)      | 1 (2%)     |              |
| Renal Tubule, Inflammation, Suppurative              |                |           |             |            | 1 (2%)       |
| Renal Tubule, Mineral                                | 5 (10%)        | 6 (12%)   | 8 (16%)     | 16 (33%)   | 8 (16%)      |

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 20614 - 01

Test Type: CHRONIC

Route: DOSED FEED

Species/Strain: RATS/HSD

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**

Perfluorooctanoic Acid

CAS Number: 335-67-1

Date Report Requested: 07/25/2018

Time Report Requested: 12:58:26

First Dose M/F: 10/27/08 / 10/28/08

Lab: BAT

---

| Harlan Sprague Dawley RATS FEMALE | 0/0 ppm | 0/300 ppm | 150/300 ppm | 0/1000 ppm | 300/1000 ppm |
|-----------------------------------|---------|-----------|-------------|------------|--------------|
| Renal Tubule, Necrosis            |         |           |             |            | 1 (2%)       |
| Urinary Bladder                   | (50)    | (49)      | (50)        | (48)       | (50)         |
| Inflammation                      |         |           |             | 4 (8%)     | 1 (2%)       |
| Metaplasia, Squamous              |         |           |             |            | 1 (2%)       |

---

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion